Illumina CEO Jacob Thaysen: Anchoring “In China, For China” to Drive a New Chapter in China’s Healthcare Through Technology

China’s life sciences industry is entering a transformative era, with a clear focus on pharmaceutical innovation, precision diagnosis, and health management. This evolution lies in genomic sequencing technology to drive breakthroughs across research and clinical applications.

As a prominent force in DNA sequencing and array-based technologies, Illumina has been deeply committed to China for two decades. Despite market challenges, Illumina remains steadfast in its mission to serve China’s healthcare and life science industries.